Vir Biotechnology, Inc.
VIR
$10.87
-$0.31-2.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 824,051.72% | -100.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 824,051.72% | -100.05% | |||
| Cost of Revenue | 23.20% | 24.14% | |||
| Gross Profit | 194.38% | -350.44% | |||
| SG&A Expenses | 29.38% | -1.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.28% | 18.81% | |||
| Operating Income | 155.16% | -177.45% | |||
| Income Before Tax | 163.94% | -191.51% | |||
| Income Tax Expenses | 5.29% | 224.09% | |||
| Earnings from Continuing Operations | 163.71% | -192.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 163.71% | -192.84% | |||
| EBIT | 155.16% | -177.45% | |||
| EBITDA | 158.50% | -189.05% | |||
| EPS Basic | 155.98% | -176.68% | |||
| Normalized Basic EPS | 157.05% | -194.23% | |||
| EPS Diluted | 155.10% | -176.68% | |||
| Normalized Diluted EPS | 156.66% | -194.23% | |||
| Average Basic Shares Outstanding | 13.82% | 5.84% | |||
| Average Diluted Shares Outstanding | 14.61% | 5.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||